

Invitation to brain surgery simulation

Copenhagen, Denmark, 13 May 2026 – FluoGuide A/S ("FluoGuide" or the "Company") is inviting investors to an event on Tuesday, June 2, 2026, where participants will get a close-up look at the company's technology and clinical applications through a live brain surgery simulation using FluoGuide's drug candidate FG001.

The attendees will have the opportunity to

- Do a live microscope-based simulation of brain surgery and experience the difference between surgery performed with and without FG001.
- Meet Dr Jane Skjøth-Rasmussen, MD, PhD. neurosurgeon at Rigshospitalet, who leads the Danish clinical trials in brain tumors with FG001 and has performed the highest number of surgeries using FG001 to date.
- Learn about the practical implications of FluoGuide's: FDA Fast Track designation and IND (Investigational New Drug) clearance for the U.S. market.
- Gain insight into the clinical results for FG001 and upcoming milestones in aggressive brain cancer and head & neck cancer.

Time and Location

- Date: Tuesday, June 2, 2026
- Time: 16:30–18:00 CET
- Location: Titanhus, Titangade 9–13, 2200 Copenhagen.

The invitation (in Danish is enclosed). Registration is required by follow this [link](https://fluoguide.com/event/fluoguide-event/) (<https://fluoguide.com/event/fluoguide-event/>)

For further information, please contact:

Morten Albrechtsen, CEO
FluoGuide A/S
Phone: +45 24 25 62 66
E-mail: ma@fluoguide.com

About FluoGuide

FluoGuide lights up cancer to maximize surgical outcomes in oncology. FluoGuide's lead product, FG001, is designed to improve surgical precision by lighting up cancer intraoperatively. The improved precision has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision enhances the likelihood of complete cure and lower healthcare costs. FluoGuide has demonstrated that FG001 is both effective and well tolerated in several phase II clinical trials. The lead indications of FG001 are aggressive brain cancer (glioblastoma) and oral head and neck cancer. FluoGuide has entered partnerships with leading MedTech companies with the aim of accelerating development and commercialization. FluoGuide is listed on Nasdaq First North Sweden under the ticker "FLUO".

For more information on FG001 or FluoGuide's uPAR technology platform, please visit our home page www.fluoguide.com

Attachments

[Invitation to brain surgery simulation](#)

[Invitation 2 Juni 2026 Brain Surgery Simulation](#)